 This Phase II study is being conducted in treatment-naive patients no previous antiviral therapy for Hepatitis C infection with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and together with Pegylated Interferon a drug approved by the Food and Drug Administration for the treatment of Hepatitis C infection. 